Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series…
Volastra Therapeutics, a clinical stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), announced completion of the…